Home
overview

This conference has already taken place.  For information on the 2010 event, please click on the link below:

 

COPD: Novel Therapeutics and Management Strategies 2010

 


For information about the 2008 Asthma & COPD conference, please see below...

 

The event as usual was highly interesting and useful from my perspective of mingling with the industry delegates and learning about their different issues”
Kevin Bacon, Founder, Chief Scientific Officer & Head, Research & Development, Actimis
 


“I very much enjoyed the conference last May and would be happy to participate in the Advisory Board for the next meeting”
Chris Compton, Executive Director Clinical Research & Development, Pfizer
 


Global asthma/COPD sales should grow to $23 billion by 2014, with inhaled corticosteroid/long-acting bronchodilator combinations set to be the leading class by value in 2014, followed by leukotriene antagonists, and anticholinergics.
 


Through a series of case studies and novel research overviews from the leading pharmaceutical companies, SMi’s 4th annual conference on Asthma & COPD will explore the new drugs in the R&D pipeline. The conference will examine patient compliance and adherence in asthma and COPD, inspect the emerging novel treatments and drug therapies, highlight the development and use of biomarkers through to the use of clinical endpoints in Asthma & COPD, as well as cover up-to-date regulatory developments from the FDA and MHRA.
 
This is your exclusive opportunity to benchmark your company by hearing from the industry leaders already at the forefront of this dynamic market.
 


OUR EXPERT PANEL OF SPEAKERS INCLUDES:
  • Dr Chris Compton, Executive Director Clinical R&D, Pfizer
  • Dr Keith Allan, Head of Global Advocacy, Novartis
  • Dr Alex Bell, Product Development Manager, 3M Healthcare
  • Dr Noel Snell, Global Medical Science Director, AstraZeneca
  • Dr Heribert Staudinger, Vice President, Clinical Development, Schering Plough
  • Dr Ewan Walters, Medical Director, Teva
  • Professor Tim Higenbottam, Global Clinical Expert, Senior Principle Scientist, AstraZeneca
  • Dr Dzelal Serdarevic, Director, A&R Therapeutic Area, Clinical R&D, Pfizer
  • Dr Shahin Sanjar, Senior Director Respiratory Sciences, Altana Pharma US
  • Dr Mark Parry-Billings, Chief Development Officer, Topigen Pharmaceuticals
  • Dr Phillip Monk, Head of Development, Synairgen
  • Dr Malinda Longphre, Clinical Director, Aerovance
  • Dr Matthew Catley, Senior Scientist, UCB
  • Dr Steve Pascoe, Global Head Respiratory/ Dermatology Profiling Exploratory Clinical Development, Novartis
  • Dr Aleck Harrison, Consultant Clinical Scientist, Vitalograph
  • Dr Hans-Juergen Smith, Product Manager Pneumonology, Viasys
  • Professor Derek Hill, CEO, Ixico

Chaired by:

  • Professor Peter Barnes, Head of Respiratory Medicine, Imperial College London
  • Dr Mark Parry-Billings, Chief Development Officer, Topigen Pharmaceuticals

7 KEY BENEFITS OF ATTENDING

 
  • GAIN a valuable insight into the current pipeline developments in the respiratory arena
  • IDENTIFY new drug developments and concepts
  • REVIEW the clinical endpoints that are currently being accepted
  • EXAMINE novel approaches to improving patient adherence and compliance
  • HEAR case studies from the world leaders in respiratory drug discovery
  • QUANTIFY the future size and scope of the asthma/COPD market and predict the future performance of key compounds
  • UNDERSTAND the latest up-to-date regulatory developments including the recent FDA draft guideline on COPD

WHO SHOULD ATTEND ASTHMA AND COPD?

 
You should attend this conference if you are an Executive, Director or scientist working in the pharmaceutical or biotech industries within:
  • Respiratory Science
  • Research & Development
  • Inflammation
  • Clinical & Regulatory Affairs
  • Drug Discovery
  • Respiratory Illness
  • Inhalation Drug Delivery
  • Project Management
  • Preclinical Development
  • Portfolio Management
  • Marketing

PREVIOUS DELEGATES HAVE BEEN FROM THE FOLLOWING COMPANIES:

  • Pfizer
  • GlaxoSmithKline
  • Merck
  • Novartis
  • AstraZeneca
  • Wyeth
  • Sanofi-Aventis
  • Astellas
  • Roche
  • UCB
  • Teva
  • Eli Lilly
  • Boehringer-Ingelheim
  • Abbott
  • Amgen
  • Schering Plough
  • MHRA
  • Taligen Therapeutics, Inc.
  • Wood Mackenzie
  • Merck Sharp & Dohme
  • Thomson Scientific
  • MD Biosciences
  • Laboratorios Almirall
  • Biolipox
  • Biota
  • 3M Healthcare
  • Ono Pharma UK Ltd
  • Dyax Corporation
  • Nspire Health
  • Elbion GmbH
  • NeuroSearch A/S
  • Activaero
  • CRS Group
  • Mundipharma
  • Merck Serono
  • CESP

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Peter Barnes

Peter Barnes, Professor of Thoracic Medicine, Imperial College

9:10 RESPIRATORY CALLS FOR THE INNOVATIVE MEDICINES INITIATIVE (IMI)

Chris Compton

Chris Compton, Executive Director, Pfizer

  • The IMI Strategic Research Agenda and the identified bottlenecks for delivering new medicines to patients with respiratory disease
  • The respiratory calls for research proposals to address the bottlenecks
  • 9:50 PROBLEMS WITH MEASURING THE EFFECT OF COPD TRIALS

    Tim Higenbottam

    Tim Higenbottam, Associate Director, AstraZeneca

  • Overcoming problems with lung function as a primary endpoint
  • COPD linked to co-morbidities (CV/GI, metabolic and orthopaedic disease)
  • Targeting co-morbidities to combating COPD
  • Alternative clinical endpoints as progression predictors in COPD
  • 10:30 Morning Coffee

    11:00 THE CONSEQUENCES OF COMPLIANCE AND NON COMPLIANCE OF ASTHMA PATIENTS

    Ewan Walters

    Ewan Walters, Medical Director, Teva UK Ltd

  • Relating asthma to the BTS guidelines
  • Step 1 – Beta antagonists
  • Step 2 – Steroids
  • Step 3 – Problems associated with single inhalers
  • Selecting and adhering to treatment
  • Differences in inhaled therapy between asthma and COPD
  • 11:40 NOVEL IMAGING MARKERS FOR THE USE OF IMAGING IN CLINICAL TRIALS

    Derek Hill

    Derek Hill, CEO, IXICO Ltd

  • Role of imaging in respiratory diseases
  • Use of CT, MRI and PET in lung imaging
  • Challenges of  imaging lungs for clinical trials
  • 12:20 Networking Lunch

    13:40 IMPROVING THE MANAGEMENT OF PATIENT CARE IN ASTHMA

    Keith Allan

    Keith Allan, Head of Global Advocacy, Novartis

  • Improving communication and understanding between patients and physicians
  • Patient suggestions for improvements
  • Improving patient education around the illness and treatment
  • Novel and improved combination therapy techniques
  • The benefits of more than one pharmacological approach
  • 14:20 IMPULSE OSCILLOMETRY

    Hans-Juergen Smith

    Hans-Juergen Smith, Product Manager , VIASYS

  • Clinical significance of oscillometric examinations
  • Methodological aspects
  • Diagnostics of obstructive lung diseases
  • Differential diagnostic potential
  • Detection of expiratory flow limitation at rest
  • 15:00 Afternoon Tea

    15:30 APPLICATION OF ANTISENSE OLIGONUCLEOTIDES IN ASTHMA AND COPD

    Mark  Parry-Billings

    Mark Parry-Billings, Chief Development Officer, Topigen Pharmaceuticals Inc

  • Rationale for using a multitarget approach in asthma and COPD
  • Design of effective drug candidates
  • Preclinical evidence for two novel antisense products
  • Clinical positioning and findings
  • 16:10 VALUE OF HUMAN IN VITRO MODELS IN ASTHMA AS A DISCOVERY AND VALIDATION TOOL

    Phillip Monk

    Phillip Monk, Head of Development, Synairgen Ltd

    16:50 POTENTIAL HOST DEFENCE PROBLEMS WITH NOVEL IMMUNOMODULATORS IN ASTHMA & COPD

    Noel Snell

    Noel Snell, Global Medical Science Director, Emerging Respiratory Projects , AstraZeneca

  • Conventional lung function parameters
  • Expanding the pathology of COPD
  • The future for COPD progression – what to expect
  • 17:30 Chairman’s Closing Remarks and Close of Day One

    17:40 DRINKS RECEPTION SPONSORED BY VIASYS CARDINAL HEALTH

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Mark  Parry-Billings

    Mark Parry-Billings, Chief Development Officer, Topigen Pharmaceuticals Inc

    9:10 OUTCOMES AND ENDPOINTS IN COPD CLINICAL TRIALS

    Dzelal Serdarevic

    Dzelal Serdarevic, Director, A&R Therapeutic Area, Clinical R&D, , Pfizer

  • Illustrating the overlap between Asthma and COPD
  • Heterogeneous patients in terms of disease severity and progression
  • What are the most appropriate endpoints for clinical trials?
  • Efficacy assessment, primary and secondary endpoints
  • Regarding patient-centred outcomes as lung function changes
  • Using multidimensional tools like the BODE index for measurement
  • Exacerbations in COPD
  • Implementing the measurements of lung function, dyspnoea, exercise capacity and body mass index
  • 9:50 CAN WE BRIDGE THE GAP BETWEEN LONG TERM OUTCOME AND SHORT TERM RESPONSES TO THE TREATMENT OF COPD?

    Steve Pascoe

    Steve Pascoe, Global Head Respiratory/ Dermatology Profiling Exploratory Clinical Development, Novartis

    10:30 Morning Coffee

    11:00 THE PERFECT PROTOCOL AND DEFINITIVE DATA

    Aleck Harrison

    Aleck Harrison, Consultant Clinical Scientist, AJH Partners

  • What to include for PFTs  in CT protocols
  • Correcting errors before they become issues 
  • Visit and e-diary compliance
  • Database issues
  • 11:40 COMPLIANCE MESUREMENT IN CLINICAL TRIALS

    Axel Fischer

    Axel Fischer, Managing Director, Activaero

    12:20 Networking Lunch

    13:30 COPD DIAGNOSIS USING HYPERPLOARIZED GAS MRI

    Jan Wolber

    Jan Wolber, Technology Leader, GE Healthcare

  • Introduction of hyperpolarized gas MR technology for pulmonary imaging
  • Overview of functional parameters that can be assessed by hyperpolarized gas MRI
  • Comparison with lung function tests and other imaging modalities
  • Image analysis methodologies
  • Application of hyperpolarized gas MR in COPD - clinical results
  • 14:10 ANTI-CYTOKINE THERAPY FOR THE TREATMENT OF ASTHMA

    Matthew Catley

    Matthew Catley, Senior Scientist, UCB-Celltech

  • Clinical experience with anti-cytokine biotherapeutics for the treatment of asthma
  • Innovative therapeutic strategies
  • Alternatives to antibodies
  • 14:50 Afternoon Tea

    15:20 PROSPECTS FOR IL-4/13 ANTAGONISM IN THE TREATMENT OF ASTHMA

    Malinda Longphre

    Malinda Longphre, Medical Science Liaison & Head, Medical Affairs, Aerovance Inc

  • Review of pre-clinical mechanism and asthma model data that support a role for IL-4/13 in asthma
  • Clinical evidence of IL-4/13 importance in asthma
  • Review of current drugs in development that target IL-4/13 in the treatment of asthma
  • 16:00 ANTI-INFLAMATORY CORTICOSTEROIDS IN ASTHMA AND COPD

    Heribert Staudinger

    Heribert Staudinger, Vice President, Clinical Development Allergy, Respiratory & Clinical Immunology, Schering Plough

    16:40 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.